NCT07435038RecruitingPhase 1/2
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS.
Source: ClinicalTrials.gov · Last updated 18 Sept 2026
Brief summary (registry, in English)
Evaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 19 Jan 2026
- Start date
- 29 Jan 2026
- Primary completion date
- 28 Dec 2028
- Lead sponsor
- Betta Pharmaceuticals Co., Ltd.
- Diseases
- Lung cancer, Pancreatic cancer, Colorectal cancer
- NCT number
- NCT07435038
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 120
- From 29 Jan 2026 to the primary completion date, 28 Dec 2028
- 7 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy
Other illness
- Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication.
Other
- Primary central nervous system (CNS) tumors active and untreated brain metastases.
Who the study is looking for
- Histologically confirmed advanced solid tumor with RAS mutations identified through deoxyribonucleic acid (DNA) sequencing.
- Have received prior standard therapy appropriate for tumor type and stage.
- Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Adequate organ function.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Southern Oncology Clinical Research Unit (SOCRU) Coordinator of this site? Confirm its status | Bedford Park | Australia | Not yet recruiting |
| Blacktown Hospital Coordinator of this site? Confirm its status | Blacktown | Australia | Not yet recruiting |
| Warringal Private Hospital Coordinator of this site? Confirm its status | Heidelberg | Australia | Not yet recruiting |
| Linear Clinical Research Ltd Coordinator of this site? Confirm its status | Nedlands | Australia | Not yet recruiting |
| Scientia Clinical Research Coordinator of this site? Confirm its status | Randwick | Australia | Not yet recruiting |
| GenesisCare St Leonards, 7 Westbourne St, St Leonards Coordinator of this site? Confirm its status | Sydney | Australia | Not yet recruiting |
| Zhejiang Cancer Hospital Coordinator of this site? Confirm its status | Hangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.